- QMRO Home
- Barts Cancer Institute
- Centre for Molecular Oncology
- Safety and efficacy of tazemetostat, an enhancer of zeste-homolog 2 inhibitor, in patients with relapsed or refractory malignant mesothelioma.
Browse
Administrators only